Melodiol Global Health Ltd
ASX:ME1

Watchlist Manager
Melodiol Global Health Ltd Logo
Melodiol Global Health Ltd
ASX:ME1
Watchlist
Price: 0.001 AUD
Market Cap: 1.1m AUD

Net Margin
Melodiol Global Health Ltd

-267.6%
Current
-555%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-267.6%
=
Net Income
-52.4m
/
Revenue
19.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Melodiol Global Health Ltd
ASX:ME1
1.1m AUD
-268%
US
Eli Lilly and Co
NYSE:LLY
954.7B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
505.3B USD
27%
CH
Roche Holding AG
SIX:ROG
253.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
16%
CH
Novartis AG
SIX:NOVN
203.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
246.3B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.7B USD
16%
No Stocks Found

Melodiol Global Health Ltd
Glance View

Market Cap
1.1m AUD
Industry
Pharmaceuticals

Melodiol Global Health Ltd is a AU-based company operating in Pharmaceuticals industry. Melodiol Global Health Limited, formerly Creso Pharma Limited, is an Australia-based cannabis company. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The company cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

ME1 Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-267.6%
=
Net Income
-52.4m
/
Revenue
19.6m
What is the Net Margin of Melodiol Global Health Ltd?

Based on Melodiol Global Health Ltd's most recent financial statements, the company has Net Margin of -267.6%.

Back to Top